Drones that transport medicines to emergency situations, urban environments or geographically-challenging locations are increasingly being utilised to improve delivery, however, there are few studies on their impact on drug stability. Here, Paul Royall and Patrick Courtney explore the implications of drone delivery on the safety and quality of medicines.
List view / Grid view
Filter the results
Now that prominent compliance deadlines are nearing in the US, Saudi Arabia and Russia and with the Falsified Medicines Directive (FMD) now in force in Europe, what is going on around the world with serialisation? Allan Bowyer provides a rundown of current events and shares insights into the challenges businesses…
In this in-depth focus are articles exploring the global situation for drug packaging serialisation as well as an assessment of using drones to deliver medicines and how this impacts safety and quality.
Darmerica LLC is voluntarily recalling two lots of quinacrine dihydrochloride due to a label mix-up.
Pharmaceutical Manufacturing Research Services has filed a lawsuit against the FDA after it rejected its application for opioids with updated labelling and appearance, meant to discourage misuse.
CPhI Worldwide will return for its 30th year on 5-7 November 2019 at Messe Frankfurt in Frankfurt, Germany.
Two Tennessee companies have been prevented from distributing drugs after a complaint they were supplying unapproved medications.
The pharmaceutical company has announced a recall for certain prescription drug bottles which do not meet child-resistant regulations.
In February this year the EU Falsified Medicines Directive (FMD) came into effect. Rich Quelch assesses this latest regulatory attempt to rid the supply chain of dangerous falsified products and reflects on the industry’s need to keep ahead of the game to future-protect itself.
SGS Life Sciences offers tailored study design and testing for extractables and leachables (E&L) in finished pharmaceutical packaging, process equipment and medical devices, and leachables in final product for clients using single-use systems (SUS).
The articles in this In-Depth Focus delve into the effectiveness of the FMD and why it is necessary as well as how drug manufacturers need to become innovative in their processes.
This issue includes an investigation into the potential for continuous production lines in biopharma, information on new guidance released by China on their regulatory processes and an assessment of the FMD to improve the drug supply chain. Also within the issue are articles on nanomedicine development, monoclonal antibodies and pharmaceutical…